• Active, not recruiting

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM

Updated: Jul 18

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma


Magrolimab

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma


The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone.


The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).


Sponsor

Gilead Sciences

 

ClinicalTrials.gov Identifier: NCT04892446

Official Title: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : May 19, 2021

Click here for details on ClinicalTrials.gov

 

Magrolimab

Magrolimab (Code C117730)

Hu5F9-G4

Magrolimab

MAGROLIMAB

anti-CD47 monoclonal antibody Hu5F9-G4

Hu5F9-G4

ONO-7913

 

Biological: Magrolimab

Drug: Daratumumab

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Bortezomib

Drug: Carfilzomib

 

Location

United States, Arizona

United States, California

United States, Michigan

United States, North Carolina

United States, Oregon

United States, Texas

United States, Virginia




Posts Archive